10-Q · August 12, 2026
STAAR reported $93.5 million of revenue, ahead of the $90.6 million consensus estimate, with gross margin of 74.5% and operating margin of 10.8%. EPS improved to $0.16 but missed the $0.19 estimate, producing a mixed…
Earnings analysis · 10-Q
STAA earnings analysis
Filed November 4, 2026 · Our reading of the company's report
The latest report
STAAR delivered $83.411 million of revenue, approximately $4.118 million above consensus, but revenue declined from $94 million in Q2 2026 and $95 million in Q3 2025. GAAP EPS of $0.11 missed the $0.14 estimate, while…
Read full summary
STAAR delivered $83.411 million of revenue, approximately $4.118 million above consensus, but revenue declined from $94 million in Q2 2026 and $95 million in Q3 2025. GAAP EPS of $0.11 missed the $0.14 estimate, while free cash flow improved to $26.380 million and cash reached $206.4 million. Underlying China and EMEA growth was positive, but China-related comparability, temporary gross-margin pressure, and the absence of formal quantitative guidance support a neutral assessment.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $0.11
- Segment
- China and EMEA reported underlying growth; exact segment revenue figures were not provided in the supplied filing text.
- Segment
- Exact segment revenue breakdown was not disclosed in the supplied filing text.
What stood out
-
Revenue beat despite sequential decline
Revenue was $83.411 million, down from $94 million in Q2 2026 and $95 million in Q3 2025, but above the $79.293 million consensus estimate by approximately $4.118 million.
-
EPS missed consensus
GAAP diluted EPS was $0.11, below the $0.14 consensus estimate and below $0.16 in Q2 2026 and $0.18 in Q3 2025.
-
Cash generation strengthened
Free cash flow was $26.380 million, improving from negative $22 million in Q1 2026 and exceeding the $19 million generated in Q2 2026.
-
Strong liquidity and capital flexibility
Cash was $206.4 million, providing liquidity while the company had no share repurchases during the quarter and retained $50.0 million under its repurchase authorization as of October 2, 2026.
-
Underlying regional growth
Underlying China and EMEA performance was described as growing, despite reported revenue comparability being affected by a prior-year $25.9 million deferred China sale.
-
Margin pressure may ease in Q4
Management expects temporary gross-margin pressure to abate in Q4 2026, with Q4 gross margins above Q3 levels, although no numeric margin target was provided.
What to watch
-
China concentration and comparability
Reported revenue fell to $83.411 million from $95 million a year earlier, with comparability affected by the prior-year $25.9 million deferred China sale, increasing China-related volatility in reported results.
-
Uncertain gross-margin recovery
Management identified temporary gross-margin pressure and provided no numeric margin target; the only forward statement was that Q4 2026 gross margins should be above Q3 levels.
-
Potential liquidity allocation tradeoff
The company authorized up to $50.0 million of repurchases but repurchased $0 during the quarter; deploying the authorization could reduce liquidity available for operating, clinical, or regulatory needs.
Management's outlook
No formal numeric revenue or EPS guidance, or explicit change to prior outlook, was provided. Management expects temporary gross-margin pressures to abate beginning in Q4 2026, with Q4 gross margins above Q3 levels.
Earlier filings 4
10-Q · May 13, 2026
STAAR Surgical reported a robust Q1 2026 with net sales of $93.5 million, a significant 119.6% increase year-over-year, indicating a strong recovery. The company achieved net income of $5.2 million or $0.10 per diluted…
10-K · March 3, 2026
STAAR Surgical describes a focused, product-led strategy centered on its EVO family of Implantable Collamer Lenses (ICLs) and reports that for the fiscal year ended January 2, 2026 approximately 100% of net sales were…
10-Q · November 5, 2025
STAAR reported Q3 net sales of $94,732,000, up from $88,590,000 in the year-ago quarter, with gross margin expanding to 82.2% and operating income rising to $18,490,000. Diluted EPS was $0.18 (vs. $0.20 a year ago) and…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.